Methyl Ergonovine Maleate Salt

• CAT Number: R008472
• CAS Number: 57432-61-8
• Molecular Formula: C24H29N3O6
• Molecular Weight: 455.511
• Purity: ≥95%
• Target: 5-HT Receptor
• Solubility: Soluble to 25 mM in sterile water
• Storage: Desiccate at RT
• IUPAC Name: (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;(Z)-but-2-enedioic acid
• InChI: InChI=1S/C20H25N3O2.C4H4O4/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13;5-3(6)1-2-4(7)8/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25);1-2H,(H,5,6)(H,7,8)/b;2-1-/t13-,14+,18-;/m1./s1
• InChIKey: NOFOWWRHEPHDCY-DAUURJMHSA-N
• SMILES: CCC(CO)NC(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C.C(=CC(=O)O)C(=O)O

Methylergonovine Maleate (CAS 57432-61-8) is the maleate salt of methylergonovine, a semi-synthetic ergot alkaloid with vasoconstrictive and uterotonic effects. Methylergonovine stimulates serotoninergic and dopaminergic receptors as well as inhibits the release of endothelial-derived relaxation factor. This results in arterial vasoconstriction and increased uterine smooth muscle contractions.

Reference

1: Bateman BT, Huybrechts KF, Hernandez-Diaz S, Liu J, Ecker JL, Avorn J.
Methylergonovine maleate and the risk of myocardial ischemia and infarction. Am J
Obstet Gynecol. 2013 Nov;209(5):459.e1-459.e13. doi: 10.1016/j.ajog.2013.07.001.
Epub 2013 Jul 11. PubMed PMID: 23850529; PubMed Central PMCID: PMC4103983.
2: Saper JR, Evans RW. Oral methylergonovine maleate for refractory migraine and
cluster headache prevention. Headache. 2013 Feb;53(2):378-81. doi:
10.1111/head.12033. Review. PubMed PMID: 23432443.
3: Hakim S, Khan RM, Maroof M, Usmani H, Huda W, Jafri F. Methylergonovine
maleate (methergine) relieves postdural puncture headache in obstetric patients.
Acta Obstet Gynecol Scand. 2005 Jan;84(1):100. PubMed PMID: 15603581.
4: Borri P, Gerli P, Antignani FL, Bindi L, Cozzi C, Moscarella G, Buzzoni P.
Methylergonovine maleate: a proposal for its more specific use. Biol Res
Pregnancy Perinatol. 1986;7(3):128-30. PubMed PMID: 3490881.
5: González P, Gayán P, Pineda G, Herrera R, Leyton M. [Plasma prolactin in the
puerperium and its relation to the use of methylergonovine maleate]. Rev Chil
Obstet Ginecol. 1984;49(3):149-55. Spanish. PubMed PMID: 6543471.
6: Narvekar MR, Pachauri S, Mhatre V, Ganguli AC. The role of methylergonovine
maleate in augmenting extraamniotic saline for midtrimester abortion. Int J
Gynaecol Obstet. 1978;15(6):545-7. PubMed PMID: 29806.
7: Kuczkowski KM. Myocardial ischemia induced by intramyometrial injection of
methylergonovine maleate. Anesthesiology. 2004 Apr;100(4):1043. PubMed PMID:
15087660.
8: Herrinton LJ, Friedman GD. Methylergonovine maleate and risk of breast cancer.
Ann Epidemiol. 1997 Aug;7(6):427-9. PubMed PMID: 9279452.
9: Mueller L, Gallagher RM, Ciervo CA. Methylergonovine maleate as a cluster
headache prophylactic: a study and review. Headache. 1997 Jul-Aug;37(7):437-42.
Review. PubMed PMID: 9277027.
10: Kirchhoefer RD. Fluoremetric determination of methylergonovine maleate and
ergonovine maleate in tablets and injections. J Assoc Off Anal Chem. 1978
Nov;61(6):1433-4. PubMed PMID: 730649.
11: Kirchhoefer RD, Wells CE. Semiautomated analysis of ergonovine maleate or
methylergonovine maleate tablets and injections by colorimetric or fluorometric
systems. J Assoc Off Anal Chem. 1975 Sep;58(5):879-83. PubMed PMID: 239918.